OPTN (Option Therapeutics) Quick Ratio: 72.45 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Option Therapeutics Quick Ratio?

Option Therapeutics OPTN Quick Ratio is 72.45 as of Dec. 2025.

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Option Therapeutics's quick ratio for the quarter that ended in Dec. 2025 was 72.45.

Option Therapeutics has a quick ratio of 72.45. It generally indicates good short-term financial strength.

The historical rank and industry rank for Option Therapeutics's Quick Ratio or its related term are showing as below:

OPTN's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.59
* Ranked among companies with meaningful Quick Ratio only.

Option Therapeutics  (AMEX:OPTN) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.

Option Therapeutics Quick Ratio Related Terms

Option Therapeutics Quick Ratio Historical Data

* Premium members only.

The historical data trend for Option Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Option Therapeutics Quick Ratio Chart

Option Therapeutics Annual Data
Trend Jun24 Jun25
Quick Ratio
4.85 3.88

Option Therapeutics Quarterly Data
Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Quick Ratio Get a 7-Day Free Trial 0.00 0.00 3.88 42.40 72.45

OPTN vs : Quick Ratio Comparison

For the Biotechnology subindustry, Option Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Option Therapeutics Quick Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Option Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Option Therapeutics's Quick Ratio falls into.


Option Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Option Therapeutics's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as

Quick Ratio (A: Jun. 2025 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.493-0)/0.127
=3.88

Option Therapeutics's Quick Ratio for the quarter that ended in Dec. 2025 is calculated as

Quick Ratio (Q: Dec. 2025 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.797-0)/0.011
=72.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Quick Ratio →
What does a Quick Ratio of 72.45 mean?
Option Therapeutics (OPTN) has a Quick Ratio of 72.45 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Option Therapeutics and its competitors.
Is Option Therapeutics' Quick Ratio too high?
Option Therapeutics' current Quick Ratio is 72.45. The Biotechnology industry median Quick Ratio is 3.59. Option Therapeutics' value of 72.45 is 1918.1% above this industry median.
How does Option Therapeutics' Quick Ratio compare to ?
Option Therapeutics' Quick Ratio of 72.45 can be compared against companies in the Biotechnology industry. The industry median Quick Ratio is 3.59. Option Therapeutics' value of 72.45 is 1918.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Option Therapeutics's current Quick Ratio of 72.45 is 1918.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Option Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Option Therapeutics's current Quick Ratio is 72.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Option Therapeutics stock overvalued right now?
Option Therapeutics (OPTN) has a current Quick Ratio of 72.45. The current Quick Ratio is 72.45 and 1918.1% above the Biotechnology industry median of 3.59. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Option Therapeutics (OPTN), the current Quick Ratio is 72.45 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Option Therapeutics Business Description

Comparable Companies
Address 680 West Nye Lane, Suite 201, Carson, NV, USA, 89703
Option Therapeutics Inc is a clinical-stage company developing inventive drug therapies to treat debilitating and life-threatening liver disease through its investigational drug candidate BIV201 (continuous infusion terlipressin). BIV201 is administered as a patent-pending liquid formulation of terlipressin with patents issued, to date, in the U.S., China, Japan, Chile, and India.